
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Paris - Topical medications should often be considered as first-line therapy in the treatment of vulval diseases because they are effective, easy to use, and fast-acting, according to Annarosa Virgili, M.D.






